Cite
MLA Citation
D. Hong et al.. “Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial.” European journal of cancer, vol. 174, n.d., pp. S72–. http://access.bl.uk/ark:/81055/vdc_100168600455.0x000045